Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 9/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 8/20 | 0.39 |
| ▸ | PRKDC | P78527 | 3/20 | 0.39 |
| ▸ | APLNR | P35414 | 5/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CCND3 | P30281 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4431730 | 0.83 | MAPK8 (0.44) | CDK2KCNH2MAPK8MAPK9MAPK10 | |
| SCHEMBL4265475 | 0.81 | CDK2 (0.50) | CDK2KCNH2MAPK8MAPK9MAPK10 | |
| SCHEMBL4296568 | 0.79 | CDK2 (0.54) | CDK2KCNH2MAPK8MAPK9MAPK10 | |
| SCHEMBL4565767 | 0.79 | CDK2 (0.44) | CDK2KCNH2CDK4CDK1CCNB1 | |
| SCHEMBL3939738 | 0.78 | CDK2 (0.53) | CDK2KCNH2MAPK8MAPK9MAPK10 | |
| SCHEMBL4252228 | 0.78 | CDK2 (0.53) | CDK2KCNH2MAPK8MAPK9MAPK10 | |
| SCHEMBL4254926 | 0.78 | CDK2 (0.49) | CDK2KCNH2MAPK8MAPK9MAPK10 | |
| SCHEMBL4425795 | 0.78 | CDK2 (0.50) | CDK2KCNH2MAPK8MAPK9MAPK10 | |
| SCHEMBL14093059 | 0.78 | CDK2 (0.43) | CDK2KCNH2CDK4CDK1CCNB1 | |
| SCHEMBL3937870 | 0.77 | MAPK1 (0.48) | CDK2KCNH2MAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046783-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | ASTRAZENACA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | ASTRAZENACA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | ASTRAZENACA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| WO-2008002245-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008002245-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | GSK3B, GSK3A, MAPT | CDK2 328/4885KCNH2 3601/4885MAPK8 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.